Brian R Murphy

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Reappraisal of the association of intussusception with the licensed live rotavirus vaccine challenges initial conclusions
    Brian R Murphy
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    J Infect Dis 187:1301-8. 2003
  2. ncbi request reprint Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines
    Brian R Murphy
    Respiratory Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 8007, USA
    Viral Immunol 15:295-323. 2002
  3. pmc Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics
    Brian R Murphy
    Respiratory Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases NIH, Building 50, Room 6517, 50 South Drive MSC 8007, Bethesda, MD 20892, USA
    J Clin Invest 110:21-7. 2002
  4. pmc Tahyna virus genetics, infectivity, and immunogenicity in mice and monkeys
    Richard S Bennett
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Virol J 8:135. 2011
  5. pmc The full genome sequence of three strains of Jamestown Canyon virus and their pathogenesis in mice or monkeys
    Richard S Bennett
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Virol J 8:136. 2011
  6. pmc Impairment of the CD8+ T cell response in lungs following infection with human respiratory syncytial virus is specific to the anatomical site rather than the virus, antigen, or route of infection
    Joshua M DiNapoli
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Virol J 5:105. 2008
  7. pmc Chimeric recombinant human metapneumoviruses with the nucleoprotein or phosphoprotein open reading frame replaced by that of avian metapneumovirus exhibit improved growth in vitro and attenuation in vivo
    Quynh N Pham
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892 8007, USA
    J Virol 79:15114-22. 2005
  8. pmc Deletion of M2 gene open reading frames 1 and 2 of human metapneumovirus: effects on RNA synthesis, attenuation, and immunogenicity
    Ursula J Buchholz
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 8007, USA
    J Virol 79:6588-97. 2005
  9. ncbi request reprint Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS
    Alexander Bukreyev
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Lancet 363:2122-7. 2004
  10. pmc Recombinant human parainfluenza virus type 2 with mutations in V that permit cellular interferon signaling are not attenuated in non-human primates
    Anne Schaap-Nutt
    Laboratory of Infectious Diseases, RNA Viruses Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Virology 406:65-79. 2010

Detail Information

Publications93

  1. ncbi request reprint Reappraisal of the association of intussusception with the licensed live rotavirus vaccine challenges initial conclusions
    Brian R Murphy
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    J Infect Dis 187:1301-8. 2003
  2. ncbi request reprint Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines
    Brian R Murphy
    Respiratory Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 8007, USA
    Viral Immunol 15:295-323. 2002
  3. pmc Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics
    Brian R Murphy
    Respiratory Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases NIH, Building 50, Room 6517, 50 South Drive MSC 8007, Bethesda, MD 20892, USA
    J Clin Invest 110:21-7. 2002
  4. pmc Tahyna virus genetics, infectivity, and immunogenicity in mice and monkeys
    Richard S Bennett
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Virol J 8:135. 2011
    ..Human infections are frequent with neutralizing antibodies present in 60-80% of the elderly population in endemic areas...
  5. pmc The full genome sequence of three strains of Jamestown Canyon virus and their pathogenesis in mice or monkeys
    Richard S Bennett
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Virol J 8:136. 2011
    ..The virus is genetically similar to Inkoo virus circulating in Europe, suggesting that much of the northern hemisphere contains JCV or similar variants...
  6. pmc Impairment of the CD8+ T cell response in lungs following infection with human respiratory syncytial virus is specific to the anatomical site rather than the virus, antigen, or route of infection
    Joshua M DiNapoli
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Virol J 5:105. 2008
    ..It was suggested that the impairment specifically suppressed the host cellular immune response, a finding that could help explain the ability of RSV to re-infect throughout life...
  7. pmc Chimeric recombinant human metapneumoviruses with the nucleoprotein or phosphoprotein open reading frame replaced by that of avian metapneumovirus exhibit improved growth in vitro and attenuation in vivo
    Quynh N Pham
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892 8007, USA
    J Virol 79:15114-22. 2005
    ..Both chimeras were comparable to wild-type HMPV in immunogenicity and protective efficacy. Thus, the P chimera is a promising live HMPV vaccine candidate that paradoxically combines improved growth in vitro with attenuation in vivo...
  8. pmc Deletion of M2 gene open reading frames 1 and 2 of human metapneumovirus: effects on RNA synthesis, attenuation, and immunogenicity
    Ursula J Buchholz
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 8007, USA
    J Virol 79:6588-97. 2005
    ..The HMPV rdeltaM2-2 virus is a promising and highly attenuated HMPV vaccine candidate...
  9. ncbi request reprint Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS
    Alexander Bukreyev
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Lancet 363:2122-7. 2004
    ..We have developed an experimental SARS vaccine for direct immunisation of the respiratory tract, the major site of SARS- coronavirus transmission and disease...
  10. pmc Recombinant human parainfluenza virus type 2 with mutations in V that permit cellular interferon signaling are not attenuated in non-human primates
    Anne Schaap-Nutt
    Laboratory of Infectious Diseases, RNA Viruses Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Virology 406:65-79. 2010
    ..This indicates that loss of HPIV2's ability to inhibit IFN signaling is insufficient to attenuate virus replication in vivo as long as IFN induction is still inhibited...
  11. pmc A novel human parainfluenza virus type 1 (HPIV1) with separated P and C genes is useful for generating C gene mutants for evaluation as live-attenuated virus vaccine candidates
    Emmalene J Bartlett
    Laboratory of Infectious Diseases, RNA Viruses Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892 2007, USA
    Vaccine 28:767-79. 2010
    ..rHPIV1-C(Delta 84-85)+P will be investigated as a potential live-attenuated vaccine candidate for HPIV1...
  12. pmc Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2
    Joseph E Blaney
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 USA
    BMC Infect Dis 4:39. 2004
    ..To prepare a vaccine candidate, a previously described 30 nucleotide deletion (Delta30) in the 3' untranslated region of DEN-4 has been engineered into the DEN-2 isolate...
  13. pmc Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1
    Joseph E Blaney
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Virol J 4:23. 2007
    ....
  14. pmc Evaluation of St. Louis encephalitis virus/dengue virus type 4 antigenic chimeric viruses in mice and rhesus monkeys
    Joseph E Blaney
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 3203, USA
    Vaccine 26:4150-9. 2008
    ..These viruses may be considered for use as SLE vaccine candidates and for use as diagnostic reagents with reduced virulence...
  15. pmc Infection of nonhuman primates with recombinant human metapneumovirus lacking the SH, G, or M2-2 protein categorizes each as a nonessential accessory protein and identifies vaccine candidates
    Stephane Biacchesi
    National Institutes of Health, NIAID, Laboratory of Infectious Diseases, Bethesda, MD 20892 8007, USA
    J Virol 79:12608-13. 2005
    ..The deltaG and deltaM2-2 viruses are promising vaccine candidates that are based on independent mechanisms of attenuation and are appropriate for clinical evaluation...
  16. ncbi request reprint Introduction of mutations into the non-structural genes or 3' untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity
    Kathryn A Hanley
    Laboratory of Infectious Diseases LID, National Institute of Allergy and Infectious Diseases NIAID, National Institutes of Health NIH, Building 50, Room 6515, 50 South Drive, MSC 8007, Bethesda, MD 20892 8007, USA
    Vaccine 22:3440-8. 2004
    ..The application of these attenuating mutations to flavivirus vaccine development is discussed...
  17. pmc The two major human metapneumovirus genetic lineages are highly related antigenically, and the fusion (F) protein is a major contributor to this antigenic relatedness
    Mario H Skiadopoulos
    Respiratory Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Disease, National Institutes of Health, Building 50, Room 6511, 50 South Dr, MSC 8007, Bethesda, MD 20892 8007, USA
    J Virol 78:6927-37. 2004
    ....
  18. pmc Generation of recombinant human parainfluenza virus type 1 vaccine candidates by importation of temperature-sensitive and attenuating mutations from heterologous paramyxoviruses
    Jason T Newman
    Respiratory Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 78:2017-28. 2004
    ..Thus, importation of attenuating mutations from heterologous viruses is an effective means for rapidly identifying mutations that attenuate HPIV1 and for generating live-attenuated HPIV1 vaccine candidates...
  19. pmc Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity
    Ursula J Buchholz
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 8007, USA
    Proc Natl Acad Sci U S A 101:9804-9. 2004
    ....
  20. ncbi request reprint Individual contributions of the human metapneumovirus F, G, and SH surface glycoproteins to the induction of neutralizing antibodies and protective immunity
    Mario H Skiadopoulos
    Respiratory Viruses Section, Laboratory of Infectious Diseases, NIAID, NIH, DHHS, Bethesda, MD 20892 8007, USA
    Virology 345:492-501. 2006
    ..Also, although the SH protein of HMPV is a virion protein that is much larger than its counterparts in previously studied paramyxoviruses, it does not appear to be a significant neutralization or protective antigen...
  21. pmc Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge
    Alexander Bukreyev
    National Institute of Allergy and Infectious Diseases, Building 50, Room 6505, NIAID, National Institutes of Health, 50 South Dr MSC 8007, Bethesda, MD 20892 8007, USA
    Virology 383:348-61. 2009
    ..Despite the attenuation, the virus was highly immunogenic, and a single IN dose completely protected the animals against a highly lethal intraperitoneal challenge of guinea pig-adapted EBOV...
  22. ncbi request reprint Mutations which enhance the replication of dengue virus type 4 and an antigenic chimeric dengue virus type 2/4 vaccine candidate in Vero cells
    Joseph E Blaney
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 50, Room 6515, 50 South Drive, MSC 8007, Bethesda, MD 20892 8007, USA
    Vaccine 21:4317-27. 2003
    ..The importance of these Vero cell adaptation mutations in flavivirus vaccine design and development is discussed...
  23. pmc A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge
    Alexander Bukreyev
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Virol 80:2267-79. 2006
    ....
  24. pmc Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3' untranslated region (3'-UTR) or by exchange of the DENV-3 3'-UTR with that of DENV-4
    Joseph E Blaney
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, United States
    Vaccine 26:817-28. 2008
    ..In addition, rDEN3Delta30/31 had reduced replication in Toxorynchites mosquitoes following intrathoracic inoculation. The results are discussed in the context of vaccine development and the physical structure of the DENV 3'-UTR...
  25. ncbi request reprint Live vaccines for human metapneumovirus designed by reverse genetics
    Ursula J Buchholz
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 50, Room 6505, 50 South Dr MSC 8007, Bethesda, MD 20892 8007, USA
    Expert Rev Vaccines 5:695-706. 2006
    ..Additional modifications to provide improved vaccines will also be discussed...
  26. pmc Successful topical respiratory tract immunization of primates against Ebola virus
    Alexander Bukreyev
    Laboratory of Infectious Disease, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 8007, USA
    J Virol 81:6379-88. 2007
    ..To our knowledge, this is the first study in which topical immunization through respiratory tract achieved prevention of a viral hemorrhagic fever infection in a primate model...
  27. pmc Recombinant human Metapneumovirus lacking the small hydrophobic SH and/or attachment G glycoprotein: deletion of G yields a promising vaccine candidate
    Stephane Biacchesi
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892 8007, USA
    J Virol 78:12877-87. 2004
    ..This indicates that SH is completely dispensable in vivo and that its deletion does not confer an attenuating effect, at least in this rodent model...
  28. ncbi request reprint Infectivity of West Nile/dengue chimeric viruses for West Nile and dengue mosquito vectors
    Kathryn A Hanley
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Vector Borne Zoonotic Dis 5:1-10. 2005
    ..This restriction in potential vectors renders it less likely that WN/DEN4 and WN/DEN4-3'delta30 would be transmitted from vaccinees to mosquitoes...
  29. ncbi request reprint An improved method for the recovery of recombinant paramyxovirus vaccine candidates suitable for use in human clinical trials
    Sonja R Surman
    Laboratory of Infectious Diseases, Respiratory Viruses Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    J Virol Methods 141:30-3. 2007
    ..Since it is likely that all live-attenuated parainfluenza virus and pneumovirus vaccines in the future will be generated using reverse genetics, this simplified method provides guidance on how this can be achieved...
  30. pmc Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates
    Alexander Bukreyev
    LID, NIAID, NIH, 50 South Dr, Rm 6505, Bethesda, MD 20892 8007, USA
    J Virol 79:13275-84. 2005
    ..NDV appears to be a promising vector for the development of vaccines for humans; one application would be in controlling localized outbreaks of emerging pathogens...
  31. ncbi request reprint Genetically modified, live attenuated dengue virus type 3 vaccine candidates
    Joseph E Blaney
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 8007, USA
    Am J Trop Med Hyg 71:811-21. 2004
    ..Thus, the rDEN3/4(ME) and rDEN3/4Delta30(ME) antigenic chimeric viruses can be considered for evaluation in humans and for inclusion in a tetravalent dengue vaccine...
  32. pmc Recombinant human parainfluenza virus type 2 vaccine candidates containing a 3' genomic promoter mutation and L polymerase mutations are attenuated and protective in non-human primates
    Sheila M Nolan
    Laboratory of Infectious Diseases, Respiratory Viruses Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Vaccine 25:6409-22. 2007
    ....
  33. pmc Attenuation and efficacy of human parainfluenza virus type 1 (HPIV1) vaccine candidates containing stabilized mutations in the P/C and L genes
    Emmalene J Bartlett
    Laboratory of Infectious Diseases, Respiratory Viruses Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA
    Virol J 4:67. 2007
    ..These mutations were evaluated on the HPIV1 backbone, both individually and in combination, for attenuation, immunogenicity, and protective efficacy in African green monkeys (AGMs)...
  34. ncbi request reprint Human parainfluenza virus type I (HPIV1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeys
    Emmalene J Bartlett
    Laboratory of Infectious Diseases, Respiratory Viruses Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 50, Room 6511, 50 South Drive MSC 8007, Bethesda, MD 20892 8007, USA
    Vaccine 23:4631-46. 2005
    ..One genetically and phenotypically stable vaccine candidate, rC(R84G/F170S)L(Y942A/L992C), was attenuated and efficacious in AGMs and is a promising live attenuated intranasal HPIV1 vaccine candidate suitable for clinical evaluation...
  35. ncbi request reprint Sendai virus, a murine parainfluenza virus type 1, replicates to a level similar to human PIV1 in the upper and lower respiratory tract of African green monkeys and chimpanzees
    Mario H Skiadopoulos
    Respiratory Viruses Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Virology 297:153-60. 2002
    ..Its ability to efficiently replicate in nonhuman primates suggests that MPIV1 lacks a significant host range restriction in primates and could theoretically cause zoonotic disease in humans...
  36. pmc Codon substitution mutations at two positions in the L polymerase protein of human parainfluenza virus type 1 yield viruses with a spectrum of attenuation in vivo and increased phenotypic stability in vitro
    Josephine M McAuliffe
    Respiratory Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 78:2029-36. 2004
    ..These findings identify the use of alternative codon substitution mutations as a method that can be used to generate candidate vaccine viruses with increased genetic stability and/or a modified level of attenuation...
  37. pmc Genome sequence analysis of La Crosse virus and in vitro and in vivo phenotypes
    Richard S Bennett
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Virol J 4:41. 2007
    ..The majority of LACV infections are mild and never reported, however, serologic studies estimate infection rates of 10-30/100,000 in endemic areas...
  38. pmc Delivery to the lower respiratory tract is required for effective immunization with Newcastle disease virus-vectored vaccines intended for humans
    Joshua M DiNapoli
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 8007, USA
    Vaccine 27:1530-9. 2009
    ....
  39. pmc Human parainfluenza virus type 1 C proteins are nonessential proteins that inhibit the host interferon and apoptotic responses and are required for efficient replication in nonhuman primates
    Emmalene J Bartlett
    Laboratory of Infectious Diseases, Respiratory Viruses Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, U S Department of Health and Human Services, Bethesda, Maryland 20892 8007, USA
    J Virol 82:8965-77. 2008
    ..Thus, the C proteins of HPIV1 are nonessential but have anti-IFN and antiapoptosis activities required for virulence in primates...
  40. pmc Determinants of the host range restriction of replication of bovine parainfluenza virus type 3 in rhesus monkeys are polygenic
    Mario H Skiadopoulos
    Respiratory Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 77:1141-8. 2003
    ....
  41. pmc Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response
    Joshua M DiNapoli
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 MSC, USA
    Vaccine 29:17-25. 2010
    ..These data suggest that NDV/GP can be effective for immunization against EBOV alone, or in combination with either HPIV3/GP or another vaccine platform in a heterologous prime-boost regimen...
  42. pmc The neurovirulence and neuroinvasiveness of chimeric tick-borne encephalitis/dengue virus can be attenuated by introducing defined mutations into the envelope and NS5 protein genes and the 3' non-coding region of the genome
    Amber R Engel
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Virology 405:243-52. 2010
    ..The high level of safety in the central nervous system indicates that vDelta30/E(315)/NS5(654,655) should be further evaluated as a TBEV vaccine...
  43. ncbi request reprint Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys
    Stephen S Whitehead
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Room 6515, Building 50, 50 South Drive, Bethesda, MD 20892 8007, USA
    Vaccine 21:4307-16. 2003
    ....
  44. pmc A paramyxovirus-vectored intranasal vaccine against Ebola virus is immunogenic in vector-immune animals
    Lijuan Yang
    Laboratory of Infectious Disease, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 50 South Drive, Rm 6505, Bethesda, Maryland 20892 8007, USA
    Virology 377:255-64. 2008
    ....
  45. pmc La Crosse virus infectivity, pathogenesis, and immunogenicity in mice and monkeys
    Richard S Bennett
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Virol J 5:25. 2008
    ..As an initial step in the establishment of useful animal models to support vaccine development, we examined LACV infectivity, pathogenesis, and immunogenicity in both weanling mice and rhesus monkeys...
  46. pmc Human parainfluenza virus type 2 V protein inhibits interferon production and signaling and is required for replication in non-human primates
    Anne Schaap-Nutt
    Laboratory of Infectious Diseases, RNA Viruses Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Virology 397:285-98. 2010
    ....
  47. pmc Identification of human parainfluenza virus type 2 (HPIV-2) V protein amino acid residues that reduce binding of V to MDA5 and attenuate HPIV-2 replication in nonhuman primates
    Anne Schaap-Nutt
    LID, NIAID, NIH, 50 South Drive, Room 6511, MSC 8007, Bethesda, MD 20892, USA
    J Virol 85:4007-19. 2011
    ..Using a transient expression system, 20 additional mutant V proteins were screened for MDA5 binding, and the region spanning residues 175 to 180 was found to be essential for this activity...
  48. pmc A tick-borne Langat virus mutant that is temperature sensitive and host range restricted in neuroblastoma cells and lacks neuroinvasiveness for immunodeficient mice
    Alexander A Rumyantsev
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases NIH, 12735 Twinbrook Parkway, Twinbrook 3, Room 3W13, MSC 8133, Bethesda, MD 20892 8133, USA
    J Virol 80:1427-39. 2006
    ..An evaluation of the complete sequence of virus recovered from brain of SCID mice inoculated with LGT mutants identified sites in the LGT genome that promoted neurovirulence/neuroinvasiveness...
  49. ncbi request reprint Molecularly engineered live-attenuated chimeric West Nile/dengue virus vaccines protect rhesus monkeys from West Nile virus
    Alexander G Pletnev
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Virology 314:190-5. 2003
    ..The more attenuated vaccine candidate, WN/DEN4-3'Delta 30, will be evaluated first in our initial clinical studies...
  50. pmc Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity
    Julie H McArthur
    Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
    Am J Trop Med Hyg 79:678-84. 2008
    ..The rDEN4Delta30-200,201 is a promising candidate and can be considered for inclusion in a tetravalent dengue virus (DENV) vaccine...
  51. ncbi request reprint Attenuating mutations in the P/C gene of human parainfluenza virus type 1 (HPIV1) vaccine candidates abrogate the inhibition of both induction and signaling of type I interferon (IFN) by wild-type HPIV1
    William Van Cleve
    Laboratory of Infectious Diseases, Respiratory Viruses Section, NIH, Bldg 50, Room 6511 50 South Drive MSC 8007 Bethesda, MD 20892 8007, USA
    Virology 352:61-73. 2006
    ....
  52. ncbi request reprint Rapid human metapneumovirus microneutralization assay based on green fluorescent protein expression
    Stephane Biacchesi
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Building 50, Room 6505, 50 South Drive, MSC 8007 Bethesda, MD 20892 8007, USA
    J Virol Methods 128:192-7. 2005
    ..This assay also permits automation and up-scaling, making it suitable for broad HMPV seroepidemiology studies and experiments that require large scale serology, such as vaccine studies...
  53. ncbi request reprint A hexavalent human rotavirus-bovine rotavirus (UK) reassortant vaccine designed for use in developing countries and delivered in a schedule with the potential to eliminate the risk of intussusception
    Albert Z Kapikian
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Infect Dis 192:S22-9. 2005
    ..e., ages 3-4 months through age 9 months). In this way, there may be the potential to eliminate or at least significantly decrease the risk of intussusception associated with rotavirus vaccination...
  54. ncbi request reprint Live-attenuated intranasal parainfluenza virus type 2 vaccine candidates developed by reverse genetics containing L polymerase protein mutations imported from heterologous paramyxoviruses
    Sheila M Nolan
    Laboratory of Infectious Diseases, Respiratory Viruses Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 50 South Drive, Building 50, Room 6509, MSC 8007, Bethesda, MD 20892, USA
    Vaccine 23:4765-74. 2005
    ..rHPIV2s bearing these modified mutations exhibited enhanced attenuation. The genetically stabilized mutations conferring a high level of attenuation will be useful in generating a live-attenuated virus vaccine for HPIV2...
  55. pmc Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens
    Joshua M DiNapoli
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 104:9788-93. 2007
    ..NDV has the potential for further development as a pretested, highly attenuated, intranasal vector to be available for expedited vaccine development for humans, who generally lack preexisting immunity against NDV...
  56. pmc Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys
    Joseph E Blaney
    Laboratory of Infectious Diseases, NIH, NIAID, LID Twinbrook III, Room 3W 13, 12735 Twinbrook Parkway, MSC 8133, Bethesda, MD 20892 8133, USA
    J Virol 79:5516-28. 2005
    ..However, two doses of TV-2 or TV-3 induced protection against DEN2 challenge. Two tetravalent formulations, TV-2 and TV-3, possess properties of a successful DEN vaccine and can be considered for evaluation in clinical trials...
  57. pmc Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus
    Joshua M DiNapoli
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases NIH, 50 South Drive, Bethesda, MD 20892, USA
    J Virol 81:11560-8. 2007
    ..This vaccine is a candidate for clinical evaluation in humans...
  58. pmc A single dose of the DENV-1 candidate vaccine rDEN1Δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial
    Anna P Durbin
    Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
    PLoS Negl Trop Dis 5:e1267. 2011
    ..The promising safety and immunogenicity profile of this vaccine confirms its suitability for inclusion in a tetravalent dengue vaccine...
  59. pmc Modification of the trypsin-dependent cleavage activation site of the human metapneumovirus fusion protein to be trypsin independent does not increase replication or spread in rodents or nonhuman primates
    Stephane Biacchesi
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892 8007, USA
    J Virol 80:5798-806. 2006
    ..These results suggest that cleavage activation is not a major determinant of HMPV virulence...
  60. pmc Targeted mutagenesis as a rational approach to dengue virus vaccine development
    Joseph E Blaney
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 33 North Drive, Room 3W10A, Bethesda, MD 20892 3203, USA
    Curr Top Microbiol Immunol 338:145-58. 2010
    ..Clinical studies of rDEN4Delta30-4995 are ongoing...
  61. pmc The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes
    Alexander Bukreyev
    LID, NIAID, NIH, 50 South Drive, Room 6505, Bethesda, MD 20892 8007, USA
    J Virol 82:12191-204. 2008
    ..Thus, sG helps RSV escape the antibody-dependent restriction of replication via effects as an antigen decoy and as a modulator of leukocytes bearing Fc gamma receptors...
  62. pmc Frequent frameshift and point mutations in the SH gene of human metapneumovirus passaged in vitro
    Stephane Biacchesi
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892 8007, USA
    J Virol 81:6057-67. 2007
    ..Adaptation involving the functional loss of a gene is unusual for an RNA virus...
  63. pmc Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic
    Alexander A Bukreyev
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Virology 399:290-8. 2010
    ..These data suggest that HPIV3/EboGP will be immunogenic in adults as well as children...
  64. ncbi request reprint Evaluation of the replication and immunogenicity of recombinant human parainfluenza virus type 3 vectors expressing up to three foreign glycoproteins
    Mario H Skiadopoulos
    Respiratory Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Virology 297:136-52. 2002
    ..Thus, it is possible to use a single HPIV vector expressing two foreign gene inserts to protect infants and young children from the severe lower respiratory tract disease caused by the three major human PIV pathogens...
  65. ncbi request reprint A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice
    Zhi Yong Yang
    Vaccine Research Center, NIAID, National Institutes of Health, Building 40, Room 4502, MSC 3005, 40 Convent Drive, Bethesda, Maryland 20892 3005, USA
    Nature 428:561-4. 2004
    ..Gene-based vaccination for the SARS-CoV elicits effective immune responses that generate protective immunity in an animal model...
  66. pmc More antibody with less antigen: can immunogenicity of attenuated live virus vaccines be improved?
    Alexander Bukreyev
    Respiratory Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 50 South Drive, Room 6517, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 99:16987-91. 2002
    ..Thus, it might be possible to develop live-attenuated vaccines that are as immunogenic as parental WT virus or, possibly, even more so...
  67. pmc Recombinant respiratory syncytial virus with the G and F genes shifted to the promoter-proximal positions
    Christine Krempl
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892 8007, USA
    J Virol 76:11931-42. 2002
    ....
  68. ncbi request reprint Comparison of live and inactivated tick-borne encephalitis virus vaccines for safety, immunogenicity and efficacy in rhesus monkeys
    Alexander A Rumyantsev
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, MSC 8133, Bethesda, MD 20892 8133, USA
    Vaccine 24:133-43. 2006
    ..These results indicate that both TBEV/DEN4Delta30 and LGT/DEN4 are safe and efficacious in rhesus monkeys and should be further evaluated as vaccine candidates for use in humans...
  69. pmc Growth restriction of an experimental live attenuated human parainfluenza virus type 2 vaccine in human ciliated airway epithelium in vitro parallels attenuation in African green monkeys
    Anne Schaap-Nutt
    Laboratory of Infectious Diseases, RNA Viruses Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892 2007, USA
    Vaccine 28:2788-98. 2010
    ..This restriction paralleled attenuation in the upper and lower respiratory tract of African green monkeys, supporting the HAE model as an appropriate and convenient system for characterizing HPIV2 vaccine candidates...
  70. pmc Role of interferon in the replication of human parainfluenza virus type 1 wild type and mutant viruses in human ciliated airway epithelium
    Emmalene J Bartlett
    Laboratory of Infectious Diseases, Respiratory Viruses Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892 2007, USA
    J Virol 82:8059-70. 2008
    ....
  71. pmc The C proteins of human parainfluenza virus type 1 (HPIV1) control the transcription of a broad array of cellular genes that would otherwise respond to HPIV1 infection
    Jim B Boonyaratanakornkit
    Laboratory of Infectious Diseases, Respiratory Viruses Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892 8007, USA
    J Virol 83:1892-910. 2009
    ..Thus, changes in host cell transcription did not reflect the striking phenotypic differences observed between these two viruses...
  72. ncbi request reprint The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers
    Anna P Durbin
    Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
    Hum Vaccin 2:167-73. 2006
    ..These promising preclinical studies have identified rDEN1Delta30 as a candidate DEN1 vaccine virus for further testing in a human Phase I clinical trial...
  73. pmc Codon stabilization analysis of the "248" temperature sensitive mutation for increased phenotypic stability of respiratory syncytial virus vaccine candidates
    Cindy Luongo
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892 8007, USA
    Vaccine 27:5667-76. 2009
    ....
  74. ncbi request reprint Sequence analysis of the Washington/1964 strain of human parainfluenza virus type 1 (HPIV1) and recovery and characterization of wild-type recombinant HPIV1 produced by reverse genetics
    Jason T Newman
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 0720, USA
    Virus Genes 24:77-92. 2002
    ..This rHPIV1 can now be used to study the biological properties of HPIV1 and as a substrate to introduce attenuating mutations for the generation of live-attenuated HPIV1 vaccine candidates...
  75. pmc A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3' untranslated region is highly attenuated and immunogenic in monkeys
    Stephen S Whitehead
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 77:1653-7. 2003
    ..The ability of the Delta30 mutation to attenuate both DEN1 and DEN4 viruses suggests that a tetravalent DEN vaccine could be generated by introduction of the Delta30 mutation into wt DEN viruses belonging to each of the four serotypes...
  76. ncbi request reprint A trade-off in replication in mosquito versus mammalian systems conferred by a point mutation in the NS4B protein of dengue virus type 4
    Kathryn A Hanley
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Virology 312:222-32. 2003
    ..The opposing effects of the NS4B P101L mutation in mosquito and vertebrate systems suggest that the NS4B protein is involved in maintaining the balance between efficient replication in the mosquito vector and the human host...
  77. pmc The genome length of human parainfluenza virus type 2 follows the rule of six, and recombinant viruses recovered from non-polyhexameric-length antigenomic cDNAs contain a biased distribution of correcting mutations
    Mario H Skiadopoulos
    Respiratory Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 77:270-9. 2003
    ..These results demonstrate, in the context of complete infectious virus, that HPIV2 has a strong and seemingly absolute requirement for a polyhexameric genome...
  78. pmc Cellular inflammatory response to flaviviruses in the central nervous system of a primate host
    Olga A Maximova
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892 3203, USA
    J Histochem Cytochem 57:973-89. 2009
    ....
  79. ncbi request reprint Genetic diversity between human metapneumovirus subgroups
    Stephane Biacchesi
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 8007, USA
    Virology 315:1-9. 2003
    ..It is reasonable to anticipate that the two genetic subgroups of HMPV represent antigenic subgroups approximately comparable to those of HRSV...
  80. pmc Paired charge-to-alanine mutagenesis of dengue virus type 4 NS5 generates mutants with temperature-sensitive, host range, and mouse attenuation phenotypes
    Kathryn A Hanley
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 76:525-31. 2002
    ..This large set of charge-to-alanine mutations specifying a wide range of attenuation for mouse brain should prove useful in fine-tuning recombinant live attenuated DEN vaccines...
  81. pmc Nonsegmented negative-strand viruses as vaccine vectors
    Alexander Bukreyev
    Building 50, Room 6505, NIAID, NIH, 50 South Dr, MSC 8007, Bethesda, MD 20892 8007, USA
    J Virol 80:10293-306. 2006
  82. ncbi request reprint Prospects for a dengue virus vaccine
    Stephen S Whitehead
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Rev Microbiol 5:518-28. 2007
    ..In this Review we discuss the unique immunological concerns in dengue virus vaccine development and the current prospects for the development of an acceptable vaccine, a goal that is likely to be reached in the near future...
  83. ncbi request reprint Introducing point and deletion mutations into the P/C gene of human parainfluenza virus type 1 (HPIV1) by reverse genetics generates attenuated and efficacious vaccine candidates
    Emmalene J Bartlett
    Laboratory of Infectious Diseases, Respiratory Viruses Section, National Institute of Allergy and Infectious Diseases, National Institute of Health, Department of Health and Human Services, Bethesda, MD 20892 8007, USA
    Vaccine 24:2674-84. 2006
    ..This virus will be evaluated clinically as a live intranasal HPIV1 vaccine, one that can be further attenuated as necessary by the introduction of additional stabilized att mutations previously developed in the L protein...
  84. pmc Comparative neuropathogenesis and neurovirulence of attenuated flaviviruses in nonhuman primates
    Olga A Maximova
    Center for Biologics Evaluation and Research, U S Food and Drug Administration, Rockville, Maryland 20852, USA
    J Virol 82:5255-68. 2008
    ..These results provide insight into the neuropathogenesis associated with attenuated flaviviruses that may guide the design of safe vaccines...
  85. ncbi request reprint The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans
    Peter F Wright
    Division of Pediatric Infectious Disease, Vanderbilt University Medical Center, Nashville, TN 37232, USA
    J Infect Dis 193:573-81. 2006
    ..In the present study, the NS2 gene, whose encoded protein antagonizes the host's interferon- alpha / beta response, was deleted from RSV vaccine candidates by use of reverse genetics...
  86. ncbi request reprint Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers
    Shabir A Madhi
    University of the Witwatersrand Medical Research Council Respiratory and Meningeal Pathogens Research Unit, South Africa
    Vaccine 24:2432-9. 2006
    ..This study examined the transmissibility between young children of an intranasally administered live attenuated human parainfluenza virus type 3 (HPIV3)-cp45 vaccine candidate...
  87. pmc What are the risks--hypothetical and observed--of recombination involving live vaccines and vaccine vectors based on nonsegmented negative-strain RNA viruses?
    Peter L Collins
    J Virol 82:9805-6. 2008
  88. pmc Evaluation of the Langat/dengue 4 chimeric virus as a live attenuated tick-borne encephalitis vaccine for safety and immunogenicity in healthy adult volunteers
    Peter F Wright
    Department of Pediatrics, Division of Pediatric Infectious Disease, Vanderbilt University Medical Center, Nashville, TN, USA
    Vaccine 26:882-90. 2008
    ..To provide a sufficient level of immunity to widely prevalent, highly neurovirulent strains of TBEV in humans, vaccine candidates will likely need to be based on the TBEV structural protein genes...
  89. ncbi request reprint Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants
    Ruth A Karron
    Center for Immunization Research, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland 21205, USA
    J Infect Dis 191:1093-104. 2005
    ..Recombination technology can be used to create live attenuated respiratory syncytial virus (RSV) vaccines that contain combinations of known attenuating mutations...
  90. ncbi request reprint rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers
    Anna P Durbin
    Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205, USA
    J Infect Dis 191:710-8. 2005
    ..The live attenuated dengue virus type 4 (DEN-4) vaccine candidate virus rDEN4 Delta 30 was previously found to be safe and immunogenic at a dose of 10(5) plaque-forming units (pfu)...
  91. ncbi request reprint A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants
    Ruth A Karron
    Pediatr Infect Dis J 22:394-405. 2003
    ..Parainfluenza type 3 virus (PIV-3) infections cause lower respiratory tract illness in children throughout the world. A licensed PIV-3 vaccine is not yet available...
  92. ncbi request reprint An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus
    Elisabetta Traggiai
    Institute for Research in Biomedicine, Via Vela 6, CH 6500 Belllinzona, Switzerland
    Nat Med 10:871-5. 2004
    ..These results show that it is possible to interrogate the memory repertoire of immune donors to rapidly and efficiently isolate neutralizing antibodies that have been selected in the course of natural infection...
  93. ncbi request reprint rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adults
    Anna P Durbin
    Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
    Hum Vaccin 2:255-60. 2006
    ..The Delta30 mutation remained unchanged in each isolate, confirming the stability of the Delta30 mutation. Further evaluation of this vaccine in a tetravalent formulation is warranted...